Literature DB >> 12831485

The organisation of head and neck oncology services in the UK: The Royal College of Surgeons of England and British Association of Head and Neck Oncologists' preliminary multidisciplinary head and neck oncology audit.

Martin Birchall1, Peter M Brown, John Browne.   

Abstract

This study was a collaboration between The Royal College of Surgeons of England Clinical Effectiveness Unit and the British Association of Head and Neck Oncologists (BAHNO). We created a multidisciplinary database through an enquiry to all 49 UK radiotherapy centres. A questionnaire audit identified teams and individuals in the UK involved with treatment of head and neck cancer. A questionnaire on their organisation, and intentions for change was sent to the 108 teams (90% response) and 11 sole practitioners (45% response) identified. Overall, 335 surgical consultants were involved in the treatment of 7500 cases per annum, with large variations in size of catchment populations served by teams. Mean length of time spent with each out-patient was 11 min. Of respondents, 58% were already using the BAHNO basic dataset and more indicated intention to use it, but only 32% could actually deliver information on their work-load. More computerisation of data collection is essential, and national audit may bridge the data gap.

Entities:  

Mesh:

Year:  2003        PMID: 12831485      PMCID: PMC1964380          DOI: 10.1308/003588403321661280

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  2 in total

1.  Multidisciplinary team a prerequisite in the management of head and neck cancer?

Authors:  Jan Olofsson
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-02       Impact factor: 2.503

2.  Assessing the Development of Multidisciplinary Care: Experience of the National Cancer Institute Community Cancer Centers Program.

Authors:  Eliot L Friedman; Neetu Chawla; Paul T Morris; Kathleen M Castro; Angela C Carrigan; Irene Prabhu Das; Steven B Clauser
Journal:  J Oncol Pract       Date:  2014-10-21       Impact factor: 3.840

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.